(TheNewswire)
Calgary, Alberta – TheNewswire- July 17, 2024 - nDatalyze Corp. (“ NDAT ” or the “Corporation”) (CSE:NDAT)(OTC:NDATF) updates its DNA-related ClinicalStudy, and Mindbalanced operations.
This news release corrects the dateof the Incite Health Inc. agreement as previously announced. The datewas previously reported as June 15, 2024 when the date should be July15, 2024.
The Clinical Study
The Corporation’s belief isthat while genetic predispositions can make individuals moresusceptible to certain mental health issues, environmental factorsplay a crucial role in whether these conditions develop and how theyprogress. For instance, a person with a genetic predisposition todepression may or may not develop the condition depending on theirlife experiences and other environmental influences. The Corporationalso believes that understanding the interplay between genetics andenvironment is important to better assess mental health issues anddevelop effective treatments. The essence of the Clinical Study withYork University is to investigate the relationship between certain DNAaspects and the extensive environmental factors resident in therecords of our Reference Database when predicting probabilities ofdepression. Based on results to date, the Corporation believes, when using psychiatrist/psychologist diagnosesas the “ground truth”, the inclusion of DNAdata results in more comprehensive and nuanced predictions, returningup to 90% positive predictive values depending on optimal tuning andusing the current DNA panel. It is believed that a variety ofcurrently-available DNA panels can be incorporated thereby increasingnuance for various medical condition/DNA relationships. It was alsofound that after the DNA-enhanced model was completed, a differentmodel employing only life/environmental factors and using the sameground truth could predict similar positivepredictive values, implying that the different model can return highaccuracy analyses without DNA data . These dataanalysis models do not constitute “diagnoses” rather the predictedprobabilities may be considered adjunctive wheninforming diagnoses and associated treatment programs.
Jim Durward, CEO/CTO states: “ Although the Clinical Study is first focused on depressionand uses a pharmacogenomic DNA panel, we now believe that the overallprocess can accommodate other DNA panels that are used in theinvestigation of drug interactions and neurological predispositions. Iam very excited about the potential here.”
Mindbalanced (“MB”)Operations
During the three months since the acquisition, MB hasbeen organizing its operations under a “franchise-style” businessmodel that involves standardized service relationships with clients,DNA data collection and FDA-cleared Transcranial Magnetic Stimulation(“TMS”) treatments for certain mental conditions. The overallconcept is to combine the Corporation’s data expertise and databaseswith new DNA and TMS treatment data to help design personalizedtreatments for a variety of mental conditions. During the period,contracts were constructed to allow for regulatory variations betweenUS States, a sales pipeline was established, and on Monday, July 15, acontract was signed with Incite Health Inc. https://incitehealth.com/ (“IHI”) whereby MB will provide marketing and account managementservices related to IHI’s DNA panel offerings.
Joshua Hill, President, states: “This strategicrelationship is not only expected to become a material near-termrevenue generator, but also carries significant potential to expandthe Corporation’s Reference Database with DNA-enhanced records whichwe believe can be combined with TMS treatment data to generatehighly-personalized treatment plans.”
For Further Information, pleasecontact:
Jim Durward, CEO/CTO (technical and financialmatters)
Email: jimd@ndatalyze.com
nDatalyze Website: https://www.ndatalyze.com
Joshua Hill, President (MindbalancedSales & Marketing matters)
Email:josh@mindbalanced.org
Mindbalanced website:https://www.mindbalanced.org
About YMI: YMIuses evidence-based, objective data from whole life experiences topredict individual mental states over time and applies this knowledgetowards a fuller understanding of how mental health develops, and howto improve mental wellbeing. YMI combines supervised machine-learningwith a proprietary Reference Database to predict an individual’spredisposition toward a variety of common mental conditions, bothcurrent and forward in time. YMI is poised torevolutionize mental health diagnoses while ensuring a sustainablerevenue stream. By strategically addressing the causes ofmisdiagnosis, establishing credibility through clinical studies, andtargeting key markets, YMI aligns both societal impact and financialsuccess.
About Mindbalanced, Inc.: Mindbalanced’s vision is to redefine mentalhealthcare through an integrative, personalized approach leveragingcutting edge technology and non-invasive treatment protocols. Byharnessing evidence-based data Mindbalanced aims to predict andenhance mental wellbeing, taking into account individualpredispositions and environmental factors thereby fostering healthierand more fulfilling lives for all.
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in the policiesof the Canadian Securities Exchange) accepts responsibility for theadequacy or accuracy of this release. This news release does notconstitute an offer to sell or a solicitation of an offer to sell anyof the securities in the United States. The securities have not beenand will not be registered under the United States Securities Act of1933, as amended (the "U.S. Securities Act") or any statesecurities laws and may not be offered or sold within the UnitedStates or to U.S. Persons unless registered under the U.S. SecuritiesAct and applicable state securities laws or an exemption from suchregistration is available. The information in this news releaseincludes certain information and statements about management's view offuture events, expectations, plans and prospects that constituteforward looking statements. These statements are based uponassumptions that are subject to significant risks and uncertainties.Because of these risks and uncertainties and as a result of a varietyof factors, the actual results, expectations, achievements orperformance may differ materially from those anticipated and indicatedby these forward-looking statements. Any number of factors could causeactual results to differ materially from these forward-lookingstatements as well as future results. Although the Corporationbelieves that the expectations reflected in forward looking statementsare reasonable, it can give no assurances that the expectations of anyforward-looking statements will prove to be correct. Except asrequired by law, the Corporation disclaims any intention and assumesno obligation to update or revise any forward-looking statements toreflect actual results, whether as a result of new information, futureevents, changes in assumptions, changes in factors affecting suchforward-looking statements or otherwise.
Copyright (c) 2024 TheNewswire - All rights reserved.